Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man

The development of effective vaccines continues to be a key goal for public health bodies, governments, funding bodies and pharmaceutical companies. With new vaccines such as Shingrix targeting Shingles and Bexsero for Meningitis B, licensed in recent years, today’s population can be prote...

Full description

Bibliographic Details
Main Authors: Amy Flaxman, Katie J. Ewer
Format: Article
Language:English
Published: MDPI AG 2018-07-01
Series:Vaccines
Subjects:
Online Access:http://www.mdpi.com/2076-393X/6/3/43
id doaj-65f86ee9e00e410580586e1da9a2e775
record_format Article
spelling doaj-65f86ee9e00e410580586e1da9a2e7752020-11-25T01:41:02ZengMDPI AGVaccines2076-393X2018-07-01634310.3390/vaccines6030043vaccines6030043Methods for Measuring T-Cell Memory to Vaccination: From Mouse to ManAmy Flaxman0Katie J. Ewer1The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UKThe Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UKThe development of effective vaccines continues to be a key goal for public health bodies, governments, funding bodies and pharmaceutical companies. With new vaccines such as Shingrix targeting Shingles and Bexsero for Meningitis B, licensed in recent years, today’s population can be protected from more infectious diseases than ever before. Despite this, we are yet to license vaccines for some of the deadliest endemic diseases affecting children, such as malaria. In addition, the threat of epidemics caused by emerging pathogens is very real as exemplified by the 2014–2016 Ebola outbreak. Most licensed vaccines provide efficacy through humoral immunity and correlates of protection often quantify neutralising antibody titre. The role of T-cells in vaccine efficacy is less well understood and more complex to quantify. Defining T-cell responses which afford protection also remains a challenge, although more sophisticated assays for assessing cell-mediated immunity with the potential for higher throughput and scalability are now available and warrant review. Here we discuss the benefits of multiparameter cytokine analysis and omics approaches compared with flow cytometric and ELISpot assays. We also review technical challenges unique to clinical trial studies, including assay validation across laboratories and availability of sample type. Measuring T-cell immunogenicity alongside humoral responses provides information on the breadth of immune responses induced by vaccination. Accurately enumerating and phenotyping T-cell immunogenicity to vaccination is key for the determination of immune correlates of protection. However, identifying such T-cell parameters remains challenging without a clear understanding of the immunological mechanisms by which a T-cell-mediated response induces protection.http://www.mdpi.com/2076-393X/6/3/43T-cellmemoryvaccinepre-clinicalclinical trial
collection DOAJ
language English
format Article
sources DOAJ
author Amy Flaxman
Katie J. Ewer
spellingShingle Amy Flaxman
Katie J. Ewer
Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man
Vaccines
T-cell
memory
vaccine
pre-clinical
clinical trial
author_facet Amy Flaxman
Katie J. Ewer
author_sort Amy Flaxman
title Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man
title_short Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man
title_full Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man
title_fullStr Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man
title_full_unstemmed Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man
title_sort methods for measuring t-cell memory to vaccination: from mouse to man
publisher MDPI AG
series Vaccines
issn 2076-393X
publishDate 2018-07-01
description The development of effective vaccines continues to be a key goal for public health bodies, governments, funding bodies and pharmaceutical companies. With new vaccines such as Shingrix targeting Shingles and Bexsero for Meningitis B, licensed in recent years, today’s population can be protected from more infectious diseases than ever before. Despite this, we are yet to license vaccines for some of the deadliest endemic diseases affecting children, such as malaria. In addition, the threat of epidemics caused by emerging pathogens is very real as exemplified by the 2014–2016 Ebola outbreak. Most licensed vaccines provide efficacy through humoral immunity and correlates of protection often quantify neutralising antibody titre. The role of T-cells in vaccine efficacy is less well understood and more complex to quantify. Defining T-cell responses which afford protection also remains a challenge, although more sophisticated assays for assessing cell-mediated immunity with the potential for higher throughput and scalability are now available and warrant review. Here we discuss the benefits of multiparameter cytokine analysis and omics approaches compared with flow cytometric and ELISpot assays. We also review technical challenges unique to clinical trial studies, including assay validation across laboratories and availability of sample type. Measuring T-cell immunogenicity alongside humoral responses provides information on the breadth of immune responses induced by vaccination. Accurately enumerating and phenotyping T-cell immunogenicity to vaccination is key for the determination of immune correlates of protection. However, identifying such T-cell parameters remains challenging without a clear understanding of the immunological mechanisms by which a T-cell-mediated response induces protection.
topic T-cell
memory
vaccine
pre-clinical
clinical trial
url http://www.mdpi.com/2076-393X/6/3/43
work_keys_str_mv AT amyflaxman methodsformeasuringtcellmemorytovaccinationfrommousetoman
AT katiejewer methodsformeasuringtcellmemorytovaccinationfrommousetoman
_version_ 1725042862458929152